Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). BridgeBio Pharma's share price for the quarter that ended in Mar. 2026 was €62.84. BridgeBio Pharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 195.7 Mil. Therefore, BridgeBio Pharma's market cap for the quarter that ended in Mar. 2026 was €12,298.3 Mil.
BridgeBio Pharma's quarterly market cap
increased
from Sep. 2025 (€8,421.9 Mil) to Dec. 2025 (€12,403.1 Mil) but then
declined
from Dec. 2025 (€12,403.1 Mil) to Mar. 2026 (€12,298.3 Mil).
BridgeBio Pharma's annual market cap
declined
from Dec. 2023 (€6,583.1 Mil) to Dec. 2024 (€4,988.7 Mil) but then
increased
from Dec. 2024 (€4,988.7 Mil) to Dec. 2025 (€12,403.1 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BridgeBio Pharma's Enterprise Value for Today is €13,500.5 Mil.
BridgeBio Pharma (FRA:2CL) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
BridgeBio Pharma Market Cap Related Terms
BridgeBio Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for BridgeBio Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2CL vs EXEL, IONS, SMMT: Market Cap Comparison
For the Biotechnology subindustry, BridgeBio Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BridgeBio Pharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where BridgeBio Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
BridgeBio Pharma's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Pharma (FRA:2CL) has a Market Cap of €12,126.3 Mil as of Jun. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BridgeBio Pharma and its competitors. According to the industry distribution chart, BridgeBio Pharma ranks #22 out of 1431 companies in the Biotechnology industry, placing it in the top 1.5%.
Is BridgeBio Pharma's Market Cap too high?
BridgeBio Pharma's current Market Cap is €12,126.3 Mil. Based on the distribution chart, BridgeBio Pharma ranks #22 out of 1431 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BridgeBio Pharma has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Pharma's Market Cap compare to EXEL and IONS?
According to the Biotechnology industry distribution chart, BridgeBio Pharma ranks #22 out of 1431 companies for Market Cap. This places BridgeBio Pharma in the top 2% of its industry — outperforming the majority of peers. The industry median Market Cap is 113.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BridgeBio Pharma and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BridgeBio Pharma's current Market Cap is €12,126.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Pharma stock overvalued right now?
Based on GuruFocus' analysis, BridgeBio Pharma (FRA:2CL) is currently considered Possible Value Trap. The stock's GF Value™ is €122.43, compared to a current price of €59.93 — trading 51% below its estimated fair value. The current Market Cap is €12,126.3 Mil. BridgeBio Pharma's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For BridgeBio Pharma (FRA:2CL), the current Market Cap is €12,126.3 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?
Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued.
The current stock price of €59.93 is trading 51% below its estimated GF Value™ of €122.43.
GuruFocus considers BridgeBio Pharma to be Possible Value Trap.
Key valuation signals for FRA:2CL:
Market Cap: €12,126.3 Mil
GF Value™: €122.43 vs. price of €59.93 (51% below fair value)
No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
66GF Score
Get the complete analysis for FRA:2CL
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2CL has been successfully added to your 
